Di Meo, FrancescoIyer, AnjushreeAkama, KeithCheng, RujinYu, ChristinaCesarano, AnnamariaKurihara, NoriyoshiTenshin, HirofumiAljoufi, ArafatMarino, SilviaSoni, Rajesh K.Roda, JulieSissons, JamesVu, Ly P.Guzman, MonicaHuang, KunLaskowski, TamaraBroxmeyer, Hal E.Roodman, David G.Perna, Fabiana2024-02-272024-02-272023Di Meo F, Iyer A, Akama K, et al. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Rep Med. 2023;4(7):101110. doi:10.1016/j.xcrm.2023.101110https://hdl.handle.net/1805/38931Multiple myeloma (MM) is an incurable malignancy of plasma cells. To identify targets for MM immunotherapy, we develop an integrated pipeline based on mass spectrometry analysis of seven MM cell lines and RNA sequencing (RNA-seq) from 900+ patients. Starting from 4,000+ candidates, we identify the most highly expressed cell surface proteins. We annotate candidate protein expression in many healthy tissues and validate the expression of promising targets in 30+ patient samples with relapsed/refractory MM, as well as in primary healthy hematopoietic stem cells and T cells by flow cytometry. Six candidates (ILT3, SEMA4A, CCR1, LRRC8D, FCRL3, IL12RB1) and B cell maturation antigen (BCMA) present the most favorable profile in malignant and healthy cells. We develop a bispecific T cell engager targeting ILT3 that shows potent killing effects in vitro and decreased tumor burden and prolonged mice survival in vivo, suggesting therapeutic relevance. Our study uncovers MM-associated antigens that hold great promise for immune-based therapies of MM.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalImmune-TargetFinder pipelineMass-SpectrometryTarget discovery strategyBi-specific T cell engagerImmunotherapyMultiple myelomaPrimary patient samplesTarget antigensValidationArticle